title: Letter from the editor.
authors.affiliation: Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ellis
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D001424:Bacterial Infections / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D003226:Congresses as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D014777:Virus Diseases / Q000517:prevention & control*
chemical_list: D001428:Bacterial Vaccines; D019496:Cancer Vaccines; D014765:Viral Vaccines